ACG’s Shirwal site is the first pharmaceutical packaging site in the WEF Lighthouse Network, using digital tools to cut ...

Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...

In this forward-looking whitepaper, Blue Mountain explores how agentic AI —autonomous, context-aware AI agents—could ...

Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...

The companies’ “Change the Target. Change What’s Possible” targets the potential of Factor XIa inhibition in the development ...

FDA Commissioner Marty Makary, M.D., M.P.H., characterized the program as a “bold step” to bring manufacturing back to the US and make the domestic sector more resilient and competitive. This program ...

Nine recommendations for extending therapeutic indications reflect ongoing lifecycle management and utility expansion of ...

Discover proven strategies and innovative technologies to streamline microbial development, from early studies to GMP readiness. Learn from industry experts how to boost productivity, overcome ...

EMA recommends Rezurock (belumosudil) for chronic graft-versus-host disease, with the drug. Meetings unmet needs via ...

Financial support and mentorship are crucial for encouraging women to consider STEM careers, bridging the gap in ...

EMA recommends Kygevvi for rare thymidine kinase 2 deficiency. It is the first authorized treatment for this disease.

Vetter's €1.5 billion investment focuses on expanding commercial and clinical production, with a new plant in Saarlouis, Germany, creating up to 2,000 jobs. The US expansion prioritizes clinical ...